TaiRx, Inc. Stock Price

TPEX:6580 Community·NT$1.7b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

6580 Share Price Performance

NT$14.95

-5.40 (-26.54%)

NT$14.95

-5.40 (-26.54%)

NT$14.95

Sat, 4 Apr 26

Share Pricen/a

6580 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Adequate balance sheet with low risk.

3 Risks

1 Reward

View Full Analysis

TaiRx, Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -1.28
: 19.18%
: -918.38%
: 0%

View Full Analysis

About 6580

Founded: 2011
Employees: n/a
CEO: Du-Shieng Chien
WebsiteView website: www.trx.com.tw

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. The company was founded in 2011 and is based in Taipei, Taiwan.